<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="for new antiviral agents. Within the huge class of plant" exact="secondary" post="metabolites, resveratrol-derived stilbenoids present a wide structural diversity and"/>
 <result pre="from natural reservoirs constantly infect human population causing risks of" exact="viral" post="epidemics and pandemics [1]. In 1997, avian influenza A"/>
 <result pre="causing risks of viral epidemics and pandemics [1]. In 1997," exact="avian influenza" post="A (H5N1) directly spread from poultry to humans. In"/>
 <result pre="directly spread from poultry to humans. In 1999 a severe" exact="encephalitis" post="outbreak, caused by a new paramyxovirus (Nipah virus), occurred"/>
 <result pre="virus provoked a pandemic influenza, followed by the Middle East" exact="Respiratory" post="Syndrome (MERS), caused by a new deadly (&amp;gt;30% mortality)"/>
 <result pre="provoked a pandemic influenza, followed by the Middle East Respiratory" exact="Syndrome" post="(MERS), caused by a new deadly (&amp;gt;30% mortality) MERS-CoV"/>
 <result pre="in West Africa (2014â€&quot;2016) became the deadliest occurrence of the" exact="disease" post="since its discovery in 1976, and finally the viral"/>
 <result pre="the disease since its discovery in 1976, and finally the" exact="viral pneumonia" post="outbreak, caused by 2019-nCoV, started in China in December"/>
 <result pre="disease since its discovery in 1976, and finally the viral" exact="pneumonia" post="outbreak, caused by 2019-nCoV, started in China in December"/>
 <result pre="antiviral agents, including those against drug-resistant and vaccine immunity escaping" exact="viral" post="strains [3], or finding new therapeutic indications for existing"/>
 <result pre="order to reduce time and cost for drug development for" exact="infectious diseases" post="[4]. The urgent need of antivirals appeared since 1980s"/>
 <result pre="need of antivirals appeared since 1980s because of HIV (human" exact="immunodeficiency" post="virus) spread causing acquired immune deficiency syndrome. Zidovudine (AZT)"/>
 <result pre="since 1980s because of HIV (human immunodeficiency virus) spread causing" exact="acquired immune deficiency syndrome." post="Zidovudine (AZT) was the first anti-HIV drug approved in"/>
 <result pre="because of HIV (human immunodeficiency virus) spread causing acquired immune" exact="deficiency" post="syndrome. Zidovudine (AZT) was the first anti-HIV drug approved"/>
 <result pre="last decades because of their many bioactivities. Stilbenoids are phytoalexins," exact="secondary" post="metabolites produced by the plant as means of defence"/>
 <result pre="and their presence in plants as both constitutive and inducible" exact="secondary" post="metabolites suggest that these compounds may play an important"/>
 <result pre="olefin, and the trans isomer (E) is usually the most" exact="stable" post="and the most common in nature. Besides the diverse"/>
 <result pre="is contained in the protein capsid, forming the nucleocapsid. Some" exact="viral" post="species acquire a phospholipid-containing envelope from the host cell"/>
 <result pre="acquire a phospholipid-containing envelope from the host cell membrane during" exact="viral" post="budding (Fig.Â 2 ) [19]. The viral life cycle"/>
 <result pre="cell membrane during viral budding (Fig.Â 2 ) [19]. The" exact="viral" post="life cycle begins when the virus binds to a"/>
 <result pre="immune system cells), structurally complementary to exterior structures of the" exact="viral" post="particle (i.e. the HIV envelope glycoproteins gp120 and gp41)."/>
 <result pre="glycoproteins gp120 and gp41). After penetration into the host cell," exact="viral" post="uncoating and release of viral nucleic acids occur. Using"/>
 <result pre="penetration into the host cell, viral uncoating and release of" exact="viral" post="nucleic acids occur. Using host resources, virus starts transcription"/>
 <result pre="Using host resources, virus starts transcription and synthesis of early" exact="viral" post="proteins, like polymerase enzymes, followed by nucleic acids replication,"/>
 <result pre="nucleic acids replication, and, in the case of retrovirus, the" exact="viral" post="integrase (IN) incorporates viral nucleic acids into the host"/>
 <result pre="in the case of retrovirus, the viral integrase (IN) incorporates" exact="viral" post="nucleic acids into the host DNA. Eventually, also late"/>
 <result pre="viral nucleic acids into the host DNA. Eventually, also late" exact="viral" post="proteins undergo transcription and translation, and their assembly leads"/>
 <result pre="undergo transcription and translation, and their assembly leads to new" exact="viral" post="particles, named â€œvirionsâ€�, which can be released to infect"/>
 <result pre="cells (Fig.Â 2). In the case of influenza virus, the" exact="viral" post="enzyme neuraminidase (NA) is required to cleave residues on"/>
 <result pre="steps, or may interfere with host cell functions, which facilitate" exact="viral" post="replication [19,20]. Indeed, since viral genome encodes just for"/>
 <result pre="host cell functions, which facilitate viral replication [19,20]. Indeed, since" exact="viral" post="genome encodes just for a few structural and regulatory"/>
 <result pre="response, has been demonstrated to be an attractive target for" exact="viral" post="pathogens because it is rapidly activated during infections and"/>
 <result pre="target for viral pathogens because it is rapidly activated during" exact="infections" post="and is involved in critical steps of the host"/>
 <result pre="thus prolonging the host cell survival and gaining time for" exact="viral" post="replication and progeny production. Viruses such as HIV and"/>
 <result pre="binding sites in their promoters, whose activation results in enhanced" exact="viral" post="transcription. In these cases, molecules interfering with NF-ÎºB pathway"/>
 <result pre="boxes the most representative stilbenoids acting on major sites of" exact="viral" post="replication. (For interpretation of the references to colour in"/>
 <result pre="IC50 values as the inhibitory concentrations of antivirals needed to" exact="lower" post="by 50% the viral induced CPEs [25], which are"/>
 <result pre="inhibitory concentrations of antivirals needed to lower by 50% the" exact="viral" post="induced CPEs [25], which are morphological changes in host"/>
 <result pre="[25], which are morphological changes in host cells caused by" exact="viral" post="invasion [26]. Time-of-addition (TOA) assays may be employed to"/>
 <result pre="(TOA) assays may be employed to explore which steps of" exact="viral" post="cycle life are blocked, by adding an antiviral compound"/>
 <result pre="to the virus/host cells at different time points relative to" exact="viral" post="inoculation [27]. Other methods, such as immunoassays, flow cytometry,"/>
 <result pre="assays (i.e. NA activity assay), are also used to study" exact="viral" post="replication, to detect viral products such as DNA, RNA,"/>
 <result pre="assay), are also used to study viral replication, to detect" exact="viral" post="products such as DNA, RNA, proteins, and to identify"/>
 <result pre="of stilbenoids 3.1 Influenza viruses Influenza viruses are responsible for" exact="acute" post="respiratory infections in two billions of people, which may"/>
 <result pre="stilbenoids 3.1 Influenza viruses Influenza viruses are responsible for acute" exact="respiratory" post="infections in two billions of people, which may result"/>
 <result pre="3.1 Influenza viruses Influenza viruses are responsible for acute respiratory" exact="infections" post="in two billions of people, which may result in"/>
 <result pre="are four types of seasonal influenza viruses (A-D), but only" exact="type A" post="and B are the main responsible for human infections"/>
 <result pre="type A and B are the main responsible for human" exact="infections" post="and may cause seasonal epidemics. Influenza A virus is"/>
 <result pre="on haemagglutin (HA1-18) and neuraminidase (NA1-11) transmembrane glycoproteins [30]. The" exact="infection" post="occurs when the viral HA binds to the host"/>
 <result pre="neuraminidase (NA1-11) transmembrane glycoproteins [30]. The infection occurs when the" exact="viral" post="HA binds to the host sialic acid receptors, which"/>
 <result pre="acidic pH of the endosome triggers the fusion of the" exact="viral" post="and endosomal membranes and opens up the viral M2"/>
 <result pre="of the viral and endosomal membranes and opens up the" exact="viral" post="M2 ion channel, leading to viral ribonucleoproteins (vRNPs) release"/>
 <result pre="and opens up the viral M2 ion channel, leading to" exact="viral" post="ribonucleoproteins (vRNPs) release in the host cytoplasm and their"/>
 <result pre="the cell nucleus. After transcription and replication, mediated by the" exact="viral" post="RNA-dependent RNA polymerase (vRdRp), the vRNPs enter the host"/>
 <result pre="family (adamantanes) inhibits the virus uncoating and subsequent release of" exact="viral" post="RNA in the host cells, by blocking M2. The"/>
 <result pre="second class (neuraminidase inhibitors) targets NA preventing the release of" exact="viral" post="particles from infected cells. Compounds targeting NA have aroused"/>
 <result pre="the movement of the virus to and from sites of" exact="infection" post="in the respiratory tract [32]. The last family consists"/>
 <result pre="the virus to and from sites of infection in the" exact="respiratory" post="tract [32]. The last family consists of inhibitors of"/>
 <result pre="between addition to the medium at the same time of" exact="viral infection" post="and addition immediately after viral infection, suggesting that the"/>
 <result pre="addition to the medium at the same time of viral" exact="infection" post="and addition immediately after viral infection, suggesting that the"/>
 <result pre="the same time of viral infection and addition immediately after" exact="viral infection," post="suggesting that the active compounds did non inhibit the"/>
 <result pre="the active compounds did non inhibit the early stages of" exact="viral" post="replication (adsorption and penetration) [33]. Fig.Â 3 Structures of"/>
 <result pre="was the most active oligomer with an IC50 value eightfold" exact="lower" post="than that of ribavirin (IC50=5.54Â Î¼g/mL). Notably, the methoxy"/>
 <result pre="[34]. Influenza A may induce the inflammation of infected airway" exact="epithelial" post="cells, which produce several chemotactic cytokines, in particular RANTES"/>
 <result pre="produce several chemotactic cytokines, in particular RANTES (Regulated upon Activation," exact="Normal" post="T Cells Expressed and Secreted), a potent chemoattractant for"/>
 <result pre="CC chemokine ligand 5 (CCL5), whose expression is affected by" exact="viral" post="infections since its gene promoter regions contain recognition sites"/>
 <result pre="chemokine ligand 5 (CCL5), whose expression is affected by viral" exact="infections" post="since its gene promoter regions contain recognition sites for"/>
 <result pre="which is involved in CCL5 retinal expression in human pigment" exact="epithelial" post="cells after viral infection [36]. Various studies demonstrated the"/>
 <result pre="in CCL5 retinal expression in human pigment epithelial cells after" exact="viral infection" post="[36]. Various studies demonstrated the capability of resveratrol to"/>
 <result pre="CCL5 retinal expression in human pigment epithelial cells after viral" exact="infection" post="[36]. Various studies demonstrated the capability of resveratrol to"/>
 <result pre="on influenza A virus (H1N1)-stimulated RANTES production in human alveolar" exact="epithelial" post="cell line A549 [38]. Compounds (+)-Îµ-viniferin, (âˆ’)-viniferal, ampelopsin C,"/>
 <result pre="concentration (0.1â€&quot;1.0Â Î¼M) with EC50 (half maximal effective concentration) values" exact="lower" post="than that of resveratrol (TableÂ 1 ). Notably, the"/>
 <result pre="activator of transcription (STAT1) signaling cascades in the A549 lung" exact="epithelial" post="cells. Western blot analysis revealed that (+)-vitisin A reduced"/>
 <result pre="a potential use of (+)-vitisin A in inflammatory disorders after" exact="virus infection" post="[38]. Fig.Â 5 Structures of oligostilbenoids isolated from Vitis"/>
 <result pre="potential use of (+)-vitisin A in inflammatory disorders after virus" exact="infection" post="[38]. Fig.Â 5 Structures of oligostilbenoids isolated from Vitis"/>
 <result pre="derivatives on RANTES production and cytotoxicity in H1N1-infected human alveolar" exact="epithelial" post="cells A549 [38]. TableÂ 1 Compounds RANTES production EC50"/>
 <result pre="with the target NA (X-ray structure taken from the RSCB" exact="Protein" post="Data Bank, ID 1A4G). In the 3D QSAR studies,"/>
 <result pre="of enveloped, single-stranded positive-sense RNA viruses usually causing gastrointestinal and" exact="respiratory" post="disorders in humans and animals. Their genome accounts for"/>
 <result pre="found in any RNA viruses. Human coronaviruses often lead to" exact="respiratory" post="illnesses that may degenerate into pneumonia and severe acute"/>
 <result pre="coronaviruses often lead to respiratory illnesses that may degenerate into" exact="pneumonia" post="and severe acute lung injury [41,42]. SARS-CoV is the"/>
 <result pre="to respiratory illnesses that may degenerate into pneumonia and severe" exact="acute" post="lung injury [41,42]. SARS-CoV is the coronavirus responsible for"/>
 <result pre="is the coronavirus responsible for the epidemic of the severe" exact="acute" post="respiratory syndrome (SARS), emerged in November 2002 and lasted"/>
 <result pre="the coronavirus responsible for the epidemic of the severe acute" exact="respiratory" post="syndrome (SARS), emerged in November 2002 and lasted until"/>
 <result pre="coronavirus responsible for the epidemic of the severe acute respiratory" exact="syndrome" post="(SARS), emerged in November 2002 and lasted until July"/>
 <result pre="inhibit the cytopathic effect (CPE) in concentrationÂ 40]. MERS-CoV (Middle" exact="East Syndrome" post="Coronavirus) is a viral pathogen causing respiratory illnesses, with"/>
 <result pre="the cytopathic effect (CPE) in concentrationÂ 40]. MERS-CoV (Middle East" exact="Syndrome" post="Coronavirus) is a viral pathogen causing respiratory illnesses, with"/>
 <result pre="in concentrationÂ 40]. MERS-CoV (Middle East Syndrome Coronavirus) is a" exact="viral" post="pathogen causing respiratory illnesses, with a 34% mortality, firstly"/>
 <result pre="MERS-CoV (Middle East Syndrome Coronavirus) is a viral pathogen causing" exact="respiratory" post="illnesses, with a 34% mortality, firstly identified in Saudi"/>
 <result pre="etÂ al. [45] investigated the effect of resveratrol on MERS-CoV" exact="infection" post="and showed that the cytotoxicity of MERS-CoV-infected Vero E6"/>
 <result pre="high levels of cleaved Caspase 3 were reported after MERS-CoV" exact="infection" post="as apoptosis indicator [47], Lin etÂ al. found that"/>
 <result pre="2 (FGF-2) signalling [49], involved in MERS-CoV-induced apoptosis [50]. 3.3" exact="Hepatitis" post="C virus Hepatitis C virus (HCV) is a bloodborne"/>
 <result pre="[49], involved in MERS-CoV-induced apoptosis [50]. 3.3 Hepatitis C virus" exact="Hepatitis" post="C virus (HCV) is a bloodborne positive single-stranded RNA"/>
 <result pre="the Flaviviridae family in the Hepacivirus genus [51]. HCV causes" exact="hepatitis C" post="that can be a mild illness lasting a few"/>
 <result pre="lasting a few weeks (acute) or a lifelong and serious" exact="disease" post="(chronic). Hepatitis C may degenerate into cirrhosis and HCV"/>
 <result pre="few weeks (acute) or a lifelong and serious disease (chronic)." exact="Hepatitis" post="C may degenerate into cirrhosis and HCV is the"/>
 <result pre="lifelong and serious disease (chronic). Hepatitis C may degenerate into" exact="cirrhosis" post="and HCV is the major cause of liver cancer."/>
 <result pre="may degenerate into cirrhosis and HCV is the major cause" exact="of liver" post="cancer. Worldwide 71 million people have chronic HCV infection"/>
 <result pre="degenerate into cirrhosis and HCV is the major cause of" exact="liver cancer." post="Worldwide 71 million people have chronic HCV infection [52]."/>
 <result pre="major cause of liver cancer. Worldwide 71 million people have" exact="chronic" post="HCV infection [52]. HCV exists in seven genotypes and"/>
 <result pre="of liver cancer. Worldwide 71 million people have chronic HCV" exact="infection" post="[52]. HCV exists in seven genotypes and more than"/>
 <result pre="polymerase (vRdRp), so far there is no effective vaccine against" exact="hepatitis C," post="and new antivirals able to overcome the drug-resistance and"/>
 <result pre="side effects in the long treatment are needed [51,52]. HCV" exact="infection" post="starts with HCV nanoparticles attachment to the liver cells"/>
 <result pre="attachment to the liver cells through a multistep-process involving the" exact="viral" post="glycoproteins E1 and E2 and cellular receptors. Then, HCV"/>
 <result pre="Upon the release of the RNA into the cytoplasm, the" exact="viral" post="RNA is translated as a single polypeptide that undergoes"/>
 <result pre="a single polypeptide that undergoes co- and post-translational processes by" exact="viral" post="and cellular proteases to yield structural (Core, E1, E2)"/>
 <result pre="particular, HCV NS3 protein plays a significant role in the" exact="viral" post="life cycle [51,53,54]. The effect and the mechanism of"/>
 <result pre="mice liver. The authors demonstrated that Z-TMS interfered with the" exact="cancer" post="stem cell (CSC) marker DCLK1, microtubule dynamics and induced"/>
 <result pre="by directly binding the NS protein HCV NS3, dramatically decreasing" exact="viral" post="replication at nanomolar concentrations (EC50 valueÂ =Â 6Â nM)"/>
 <result pre="genotypes 2a (RT-PCR and Western blot). These data suggested a" exact="lower" post="potency of (âˆ’)-Ïµ-viniferin. However, similar experiments on genotype 1b"/>
 <result pre="intestinal epithelium and to intestinal first pass effects [58]. 3.4" exact="Dengue" post="virus (DENV) Dengue virus (DENV) is a mosquito-borne virus,"/>
 <result pre="to intestinal first pass effects [58]. 3.4 Dengue virus (DENV)" exact="Dengue" post="virus (DENV) is a mosquito-borne virus, causing a wide"/>
 <result pre="genome, and includes four serotypes (DENV-1-4). 100â€&quot;400 million dengue virus" exact="infections" post="are estimated each year. Dengue affects in particular South-East"/>
 <result pre="(DENV-1-4). 100â€&quot;400 million dengue virus infections are estimated each year." exact="Dengue" post="affects in particular South-East Asia (about 70% of the"/>
 <result pre="recent years. So far, there is no specific treatment for" exact="dengue fever" post="[60,61]. Various polyphenols have exhibited anti-dengue activity, such as"/>
 <result pre="an activity in the post-entry and fusion events, such as" exact="viral" post="translation, replication, or events prior to viral proteins assembly."/>
 <result pre="events, such as viral translation, replication, or events prior to" exact="viral" post="proteins assembly. Both compounds were found to inhibit RNA"/>
 <result pre="viral proteins assembly. Both compounds were found to inhibit RNA" exact="viral" post="synthesis in DENV2 replication, but they resulted inactive against"/>
 <result pre="synthesis in DENV2 replication, but they resulted inactive against the" exact="viral" post="RdRp. In a pretreatment cells study, only PNR-5-02 affected"/>
 <result pre="at least partially interactions with host cell factors required for" exact="viral" post="replication. On the other hand, PNR-4-44, inactive in the"/>
 <result pre="virus. The exact mechanism of action is not known. Interestingly," exact="Dengue" post="virus belong to the same family of HCV, sharing"/>
 <result pre="B and Ïµ-viniferin were found to inhibit HCV NS3 [57,58]," exact="Dengue" post="virus NS3 could be likely one of the possible"/>
 <result pre="still needed to improve their activity-cytotoxicity profile [66]. 3.5 Human" exact="immunodeficiency" post="virus (HIV) Human immunodeficiency virus type 1 (HIV-1) is"/>
 <result pre="their activity-cytotoxicity profile [66]. 3.5 Human immunodeficiency virus (HIV) Human" exact="immunodeficiency" post="virus type 1 (HIV-1) is an enveloped single-stranded RNA"/>
 <result pre="profile [66]. 3.5 Human immunodeficiency virus (HIV) Human immunodeficiency virus" exact="type 1" post="(HIV-1) is an enveloped single-stranded RNA virus of the"/>
 <result pre="RNA virus of the Lentiviridae family [68], responsible for the" exact="acquired immunodeficiency syndrome" post="(AIDS), which currently affects more than 37 million people"/>
 <result pre="virus of the Lentiviridae family [68], responsible for the acquired" exact="immunodeficiency" post="syndrome (AIDS), which currently affects more than 37 million"/>
 <result pre="of the Lentiviridae family [68], responsible for the acquired immunodeficiency" exact="syndrome" post="(AIDS), which currently affects more than 37 million people"/>
 <result pre="than 37 million people [69]. HIV infects CD4-positive T-helper through" exact="viral" post="envelope glycoproteins (gp120 and gp41) that recognize and bind"/>
 <result pre="that is incorporated in the cell host genome by a" exact="viral" post="integrase. At this point, as an integrated provirus, HIV"/>
 <result pre="years. The transition from latency to HIV replication and subsequent" exact="infection" post="occurs when host cellular transcription factors are activated along"/>
 <result pre="along with regulatory HIV proteins [5]. Antiretroviral drugs effectively control" exact="viral" post="replication, but the high mutation rate of HIV-1, along"/>
 <result pre="mutation rate of HIV-1, along with the huge number of" exact="viral" post="particles produced by host cells, has led to drug"/>
 <result pre="Jurkat [72]. Surprisingly, the authors found that resveratrol prevented productive" exact="infection" post="of resting CD4 T cells in a dose-dependent manner."/>
 <result pre="active at all concentrations tested, piceid and isorhapontigenin inhibited productive" exact="infection" post="at a concentration 30Â Î¼M, while piceatannol was less"/>
 <result pre="). The isolated compounds were tested in the NCI (National" exact="Cancer" post="Institute) primary anti-HIV screen: dibalanocarpol and balanocarpol showed modest"/>
 <result pre="isolated compounds were tested in the NCI (National Cancer Institute)" exact="primary" post="anti-HIV screen: dibalanocarpol and balanocarpol showed modest HIV-inhibitory activity"/>
 <result pre="response, but also mediator of the HIV fusion, binding the" exact="viral" post="envelope glycoprotein gp120. All the three compounds inhibited the"/>
 <result pre="for HIV-1 replication, catalysing the insertion of the newly synthesized" exact="viral" post="DNA into the host chromosome by two steps: 3â€²"/>
 <result pre="cleavage of the terminal dinucleotide at the 3â€²-end of the" exact="viral" post="DNA mimic, and strand transfer (ST), that is integration"/>
 <result pre="especially involving the C-terminal domain (CTD), at concentrations 10 times" exact="lower" post="than that necessary to inhibit 3â€²P and ST [77]."/>
 <result pre="&amp;gt;111 ND ND ND Cellular proteins, like NF-ÎºB, and regulatory" exact="viral" post="proteins, like Tat (transactivator of transcription), are involved in"/>
 <result pre="responses, cell transformation, apoptosis, embryonic liver development, and transcription of" exact="viral" post="genes, including HIV. NF-ÎºB is highly produced upon activation"/>
 <result pre="including HIV. NF-ÎºB is highly produced upon activation of the" exact="primary" post="human T cells, the primary HIV target, and it"/>
 <result pre="produced upon activation of the primary human T cells, the" exact="primary" post="HIV target, and it activates a complex array of"/>
 <result pre="normal part of human cells, it should not mutate, like" exact="viral" post="targets [68]. On the other hand, Tat is a"/>
 <result pre="viral targets [68]. On the other hand, Tat is a" exact="viral" post="regulatory protein, which recruits cellular factors binding the enhancer"/>
 <result pre="which attract monocytes and CD4 T lymphocytes to perpetuate the" exact="infection" post="[81]. In 2000, a synthetic stilbene compound, CGA137053 (Fig.Â"/>
 <result pre="to work intracellularly and to inhibit HIV-1 replication on HIV-infected," exact="primary" post="human leucocytes (PBL) and macrophages in a dose-dependent manner"/>
 <result pre="the synthetic stilbene compound CGA137053 binding directly Tat protein [82]." exact="Lethal" post="mutagenesis is another antiviral approach that takes advantage of"/>
 <result pre="to decreased accumulation of RT products rather than to increased" exact="viral" post="mutagenesis [86]. Fig.Â 15 Structures of resveratrol derivatives screened"/>
 <result pre="0.29â€&quot;1.69Â Î¼M (TableÂ 6 ). M8 seemed to inhibit the" exact="viral" post="attachment to host cells. Indeed, firstly in TOA assays,"/>
 <result pre="quantitative real-time PCR analysis showed a decrease level of early" exact="viral" post="reverse transcription products in a dose-dependent manner. Lastly, in"/>
 <result pre="of HIV-1 in different cells from Refs.Â [87]. TableÂ 6" exact="Variant" post="Cell line Assay EC50 (Î¼M)a CC50 (Î¼M) SI NL"/>
 <result pre="H1N1)- â†&quot; RANTES EC50Â =Â 0.27Â Î¼M on Human alveolar" exact="epithelial" post="A549 Huang [38] 2b Influenza A (A/PR/8/34, H1N1) Neuraminidase"/>
 <result pre="- HCV-1b replicon (FCA4), JFH1- HCV-2a (HCVcc) â†&quot; HCV NS5B" exact="Hepatoma" post="Huh7-derived (Huh7.5, GS5 and FCA4)FCA4-HCV+DCLK1+ Ngu yen [55] Vitisin"/>
 <result pre="(1b genotype) âˆ—âˆ— on Huh7.5 PNR-4-44 DENV-2-induced CPE â†&quot; RNA" exact="viral" post="synthesis EC50Â =Â 8.12Â nM (0.00812Â Î¼M) Han [66]"/>
 <result pre="=Â 8.12Â nM (0.00812Â Î¼M) Han [66] PNR-5-02 â†&quot; RNA" exact="viral" post="synthesis and host cell factors interference EC50Â =Â 7.22Â"/>
 <result pre="(0.00722Â Î¼M) Pterostilbene HIV-1 â†&quot; integrase, prevents CD4 T cells" exact="infection" post="Activated T and transformed T Jurkat (clone E6), IL-4"/>
 <result pre="Clouser [70] M8 HIV-1 NL 4â€&quot;3 or BaL variants â†&quot;" exact="viral" post="attachment EC50Â =Â 0.29â€&quot;1.69Â Î¼M on MT-4 and TZM-bl"/>
 <result pre="MT-4 and TZM-bl cells Han [87] 28 HNV â†&quot; RNA" exact="viral" post="replication EC50Â =Â 2.43Â Î¼M on HG23Â cells Harmalkar"/>
 <result pre="IC50Â =Â 0.0036Â nM (0.0036 â€¢ 10âˆ’3Â Î¼M) on Human" exact="rhabdomyosarcoma" post="(RD) Segun [95] Kuwanon X HSV-1 (15577 and clinical"/>
 <result pre="Kuwanon X HSV-1 (15577 and clinical strains)HSV-2 (333 strains) â†&quot;" exact="viral" post="adsorption, penetration, proteins, DNA biosynthesis, NF-ÎºB pathway IC50Â =Â"/>
 <result pre="HSV-1 strain (B2006 strain) and PAA-resistant strain Inhibition of late" exact="viral" post="proteins IC50Â =Â 19.8Â Î¼g/mL (81.0Â Î¼M) (7401H)IC50Â =Â"/>
 <result pre="human NV (HNV) is considered the major cause of epidemic" exact="acute" post="gastroenteritis worldwide, leading to 685 million cases per year."/>
 <result pre="NV (HNV) is considered the major cause of epidemic acute" exact="gastroenteritis" post="worldwide, leading to 685 million cases per year. To"/>
 <result pre="the cell ribosomes and proteins, and are transcribed by the" exact="viral" post="RNA-polymerase [90]. Harmalkar etÂ al. performed the total synthesis"/>
 <result pre="by the viral RNA-polymerase [90]. Harmalkar etÂ al. performed the" exact="total" post="synthesis of the natural gramistilbenoids A, B, C, and"/>
 <result pre="compound 28 (EC50Â =Â 2.43Â Î¼M, CC50Â 28 inhibited the" exact="viral" post="RNA genome replication probably involving the heat shock factor"/>
 <result pre="for several illnesses, such as hand-foot-and-mouth (HFM) disease, encephalitis, paralysis," exact="respiratory" post="diseases, poliomyelitis, affecting millions of people worldwide. Enteroviruses are"/>
 <result pre="and translated into a polyprotein, which is cleaved by the" exact="viral" post="proteases to yield the structural and NS proteins. The"/>
 <result pre="involved in the replication of RNA via a negative strand" exact="intermediate" post="that works as template for the synthesis of new"/>
 <result pre="be further translated and replicated, or directly encapsulated in the" exact="viral" post="capsid proteins to form new infectious virions. The viral"/>
 <result pre="directly encapsulated in the viral capsid proteins to form new" exact="infectious" post="virions. The viral proteases trigger also host cell factors,"/>
 <result pre="the viral capsid proteins to form new infectious virions. The" exact="viral" post="proteases trigger also host cell factors, which help virus"/>
 <result pre="tested for the antiviral activity against HRV1B-, CVB3- and EV71-" exact="infections" post="by Oh etÂ al. Resveratrol showed antiviral activity against"/>
 <result pre="29.7Â Î¼M. Conversely, cis-resveratrol exhibited significant antiviral activity in CVB3" exact="infection" post="with IC50 value of 12.2Â Î¼M and in EV71"/>
 <result pre="infection with IC50 value of 12.2Â Î¼M and in EV71" exact="infection" post="with IC50 value of 37.6Â Î¼M [94]. Segun etÂ"/>
 <result pre="the human population contract orofacial infections, that can lead to" exact="infectious" post="blindness and viral encephalitis in adults [97]. On the"/>
 <result pre="human population contract orofacial infections, that can lead to infectious" exact="blindness" post="and viral encephalitis in adults [97]. On the other"/>
 <result pre="contract orofacial infections, that can lead to infectious blindness and" exact="viral encephalitis" post="in adults [97]. On the other hand, HSV-2 infection"/>
 <result pre="orofacial infections, that can lead to infectious blindness and viral" exact="encephalitis" post="in adults [97]. On the other hand, HSV-2 infection"/>
 <result pre="viral encephalitis in adults [97]. On the other hand, HSV-2" exact="infection" post="affects the genital area and is a major cause"/>
 <result pre="as HIV and human papillomavirus (HPV) [98]. The transmission of" exact="herpes" post="viruses occurs from person to person by direct contact"/>
 <result pre="to person by direct contact with infected secretions [99]. The" exact="infections" post="may be latent and appear periodically, due to the"/>
 <result pre="the virus capability to infect neurons, in particular the sensorial" exact="nerve" post="termini, then traveling in a retrograde manner. Therefore, HSV"/>
 <result pre="in particular the sensorial nerve termini, then traveling in a" exact="retrograde" post="manner. Therefore, HSV may reactivate a lytic-replication cycle leading"/>
 <result pre="Therefore, HSV may reactivate a lytic-replication cycle leading to a" exact="recurrent" post="infection, viral shedding and transmission to new hosts [17,96]."/>
 <result pre="may reactivate a lytic-replication cycle leading to a recurrent infection," exact="viral" post="shedding and transmission to new hosts [17,96]. Nucleoside analogues,"/>
 <result pre="to develop new antiherpetic compounds due to the growth of" exact="herpes" post="simplex virus strains resistant to acyclovir [100]. An exhaustive"/>
 <result pre="as anti-HSV with multiple mechanisms of action, including inhibition of" exact="viral" post="adsorption and penetration, reduction of immediate-early (IE), late (L)"/>
 <result pre="penetration, reduction of immediate-early (IE), late (L) gene expression and" exact="viral" post="DNA biosynthesis, and inhibition of the NF-ÎºB activation induced"/>
 <result pre="HSV-2 in many cell lines, being necessary for initiation of" exact="viral" post="replication and viral protein synthesis. The NF-ÎºB pathway suppression"/>
 <result pre="cell lines, being necessary for initiation of viral replication and" exact="viral" post="protein synthesis. The NF-ÎºB pathway suppression has been revealed"/>
 <result pre="acted as potent virucidal when added to the medium during" exact="viral infection," post="and throughout the incubation thereafter, or immediately after infection,"/>
 <result pre="incubation thereafter, or immediately after infection, whereas ACV exhibited a" exact="lower" post="effect. This study suggested that the antiviral activity of"/>
 <result pre="[103]. In general, the compounds were more active against HSV-2" exact="infection" post="than that from HSV-1. Vaticaffinol, a tetramer with reported"/>
 <result pre="the beneficial effects of Thai traditional plants for the treatment" exact="herpes" post="simplex virus, Chuanasa etÂ al. investigated the antiviral activity"/>
 <result pre="different mechanism of action than ACV, probably inhibiting the late" exact="viral" post="protein synthesis, similarly to resveratrol. Moreover, in inÂ vivo"/>
 <result pre="provided promising results on this wide class of compounds, a" exact="limited" post="number of inÂ vivo studies has been performed so"/>
 <result pre="needed to carry out inÂ vivo experiments and remain of" exact="primary" post="importance to confirm the antiviral potential of stilbenoids for"/>
 <result pre="broad-spectrum antiviral agentsAntivir. Res.154201817418210.1016/j.antiviral.2018.04.01629698664 2LuoG.GaoS.J.Global health concerns stirred by emerging" exact="viral" post="infectionsJ.Â Med. Virol.202039940010.1002/jmv.2568331967329 3WHOWHO publishes list of top emerging"/>
 <result pre="dehydro- Îµ -viniferin for antimicrobial activity against the foodborne pathogen" exact="Listeria" post="monocytogenesInt. J. Mol. Sci.212020216810.3390/ijms21062168 11NiesenD.B.HesslerC.SeeramN.P.Beyond resveratrol: a review of"/>
 <result pre="16ZhaoX.XuJ.SongX.JiaR.YinZ.ChengA.JiaR.ZouY.LiL.YinL.YueG.LvC.JingB.Antiviral effect of resveratrol in ducklings infected with virulent duck" exact="enteritis" post="virusAntivir. Res.13020169310010.1016/j.antiviral.2016.03.01427040314 17AnnunziataG.MaistoM.SchisanoC.CiampagliaR.NarcisoV.TenoreG.C.NovellinoE.Resveratrol as a novel anti-herpes simplex virus"/>
 <result pre="virus infectionÂ : who controls whomEMBO J.2220032552256010.1093/emboj/cdg26712773372 22HiscottJ.KwonH.GÃ©ninP.HiscottJ.KwonH.GÃ©ninP.Hostile takeoversÂ :" exact="viral" post="appropriation of the NF- kB pathway Find the latest"/>
 <result pre="kB pathway Find the latest versionÂ : hostile takeoversÂ :" exact="viral" post="appropriation of the NF- Îº B pathwayJ.Â Clin. Invest.107200114315110.1172/JCI1191911160127"/>
 <result pre="25CotareloM.CatalÃ¡nP.SÃ¡nchez-CarrilloC.MenasalvasA.CercenadoE.TenorioA.BouzaE.Cytopathic effect inhibition assay for determining the in-vitro susceptibility of" exact="herpes" post="simplex virus to antiviral agentsJ.Â Antimicrob. Chemother.44199970570810.1093/jac/44.5.70510552991 26SuchmanE.BlairC.D.Cytopathic Effects"/>
 <result pre="27Aoki-UtsuboC.ChenM.HottaH.Time-of-addition and temperature-shift assays to determine particular step(s) in the" exact="viral" post="life cycle that is blocked by antiviral substance(s)Bio-Protocol82018e283010.21769/BioProtoc.2830 28MurrayP.R.The"/>
 <result pre="overviewEur. J. Clin. Microbiol. Infect. Dis.202010.1007/s10096-020-03840-9 31SamjiT.Influenza A: understanding the" exact="viral" post="life cycleYale J. Biol. Med.82200915315920027280 32HirschfeldG.WeberL.RenklA.Scharffetter- KochanekK.WeissJ.M.Anaphylaxis after Oseltamivir"/>
 <result pre="the stem bark of Shorea uliginosaPhytochem. Lett.2820181710.1016/j.phytol.2018.07.026 34LiuA.L.YangF.ZhuM.ZhouD.LinM.LeeS.M.Y.WangY.T.DuG.H.InÂ vitro anti-influenza" exact="viral" post="activities of stilbenoids from the lianas of Gnetum pendulumPlanta"/>
 <result pre="of Gnetum pendulumPlanta Med.7620101874187610.1055/s-0030-125003020539973 35MatsukuraS.KokubuF.KuboH.TomitaT.TokunagaH.KadokuraM.YamamotoT.KuroiwaY.OhnoT.SuzakiH.AdachiM.Expression of RANTES by normal airway" exact="epithelial" post="cells after Influenza virus A infectionAm. J. Respir. Cell"/>
 <result pre="A inhibits influenza A virus-induced RANTES production in A549 alveolar" exact="epithelial" post="cells through interference with Akt and STAT 1 phosphorylationPlanta"/>
 <result pre="Chem.4120061084108910.1016/j.ejmech.2006.03.02416875760 41RotaP.ObersteM.MonroeS.NixW.CampagnoliR.IcenogleJ.PeÃ±arandaS.BankampB.MaherK.ChenM.TongS.TaminA.LoweL.FraceM.DeRisiJ.ChenQ.WangD.ErdmanD.PeretT.BurnsC.KsiazekT.RollinP.SanchezA.LiffickS.HollowayB.LimorJ.McCaustlandK.Olsen-RasmussenM.FouchierR.GÃ¼ntherS.OsterhausA.DrostenC.PallanschM.AndersonL.BelliniW.Identification of a novel coronavirus in patients with severe" exact="acute" post="respiratory syndromeScience8030020031394139910.1126/science.1085952 42ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.M.E.FouchierR.A.M.Isolation of a novel coronavirus from"/>
 <result pre="41RotaP.ObersteM.MonroeS.NixW.CampagnoliR.IcenogleJ.PeÃ±arandaS.BankampB.MaherK.ChenM.TongS.TaminA.LoweL.FraceM.DeRisiJ.ChenQ.WangD.ErdmanD.PeretT.BurnsC.KsiazekT.RollinP.SanchezA.LiffickS.HollowayB.LimorJ.McCaustlandK.Olsen-RasmussenM.FouchierR.GÃ¼ntherS.OsterhausA.DrostenC.PallanschM.AndersonL.BelliniW.Identification of a novel coronavirus in patients with severe acute" exact="respiratory" post="syndromeScience8030020031394139910.1126/science.1085952 42ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.M.E.FouchierR.A.M.Isolation of a novel coronavirus from a"/>
 <result pre="42ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.M.E.FouchierR.A.M.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN.Â Engl. J. Med.36720121814182010.1056/NEJMoa121172123075143 43WHOWHO MERS Global"/>
 <result pre="challenges and the way forwardAntivir. Res.1592018354410.1016/j.antiviral.2018.09.00230236531 45LinS.C.HoC.T.ChuoW.H.LiS.WangT.T.LinC.C.Effective inhibition of MERS-CoV" exact="infection" post="by resveratrolBMC Infect. Dis.17201711010.1186/s12879-017-2253-828049444 46HockeA.C.BecherA.KnepperJ.PeterA.HollandG.TÃ¶nniesM.BauerT.T.SchneiderP.NeudeckerJ.MuthD.WendtnerC.M.RÃ¼ckertJ.C.DrostenC.GruberA.D.LaueM.SuttorpN.HippenstielS.WolffT.Emerging human middle east respiratory"/>
 <result pre="MERS-CoV infection by resveratrolBMC Infect. Dis.17201711010.1186/s12879-017-2253-828049444 46HockeA.C.BecherA.KnepperJ.PeterA.HollandG.TÃ¶nniesM.BauerT.T.SchneiderP.NeudeckerJ.MuthD.WendtnerC.M.RÃ¼ckertJ.C.DrostenC.GruberA.D.LaueM.SuttorpN.HippenstielS.WolffT.Emerging human middle east" exact="respiratory" post="syndrome coronavirus causes widespread infection and alveolar damage in"/>
 <result pre="infection by resveratrolBMC Infect. Dis.17201711010.1186/s12879-017-2253-828049444 46HockeA.C.BecherA.KnepperJ.PeterA.HollandG.TÃ¶nniesM.BauerT.T.SchneiderP.NeudeckerJ.MuthD.WendtnerC.M.RÃ¼ckertJ.C.DrostenC.GruberA.D.LaueM.SuttorpN.HippenstielS.WolffT.Emerging human middle east respiratory" exact="syndrome" post="coronavirus causes widespread infection and alveolar damage in human"/>
 <result pre="Dis.17201711010.1186/s12879-017-2253-828049444 46HockeA.C.BecherA.KnepperJ.PeterA.HollandG.TÃ¶nniesM.BauerT.T.SchneiderP.NeudeckerJ.MuthD.WendtnerC.M.RÃ¼ckertJ.C.DrostenC.GruberA.D.LaueM.SuttorpN.HippenstielS.WolffT.Emerging human middle east respiratory syndrome coronavirus causes widespread" exact="infection" post="and alveolar damage in human lungsAm. J. Respir. Crit."/>
 <result pre="in human lungsAm. J. Respir. Crit. Care Med.188201388288610.1164/rccm.201305-0954LE24083868 47ChuH.ZhouJ.WongB.H.Y.LiC.ChanJ.F.W.ChengZ.S.YangD.WangD.LeeA.C.Y.LiC.YeungM.L.CaiJ.P.ChanI.H.Y.HoW.K.ToK.K.W.ZhengB.J.YaoY.QinC.YuenK.Y.Middle East" exact="respiratory" post="syndrome coronavirus efficiently infects human primary T lymphocytes and"/>
 <result pre="human lungsAm. J. Respir. Crit. Care Med.188201388288610.1164/rccm.201305-0954LE24083868 47ChuH.ZhouJ.WongB.H.Y.LiC.ChanJ.F.W.ChengZ.S.YangD.WangD.LeeA.C.Y.LiC.YeungM.L.CaiJ.P.ChanI.H.Y.HoW.K.ToK.K.W.ZhengB.J.YaoY.QinC.YuenK.Y.Middle East respiratory" exact="syndrome" post="coronavirus efficiently infects human primary T lymphocytes and activates"/>
 <result pre="Care Med.188201388288610.1164/rccm.201305-0954LE24083868 47ChuH.ZhouJ.WongB.H.Y.LiC.ChanJ.F.W.ChengZ.S.YangD.WangD.LeeA.C.Y.LiC.YeungM.L.CaiJ.P.ChanI.H.Y.HoW.K.ToK.K.W.ZhengB.J.YaoY.QinC.YuenK.Y.Middle East respiratory syndrome coronavirus efficiently infects human" exact="primary" post="T lymphocytes and activates the extrinsic and intrinsic apoptosis"/>
 <result pre="52WHOHepatitis Chttps://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c2019 53BelonC.A.FrickD.N.Helicase inhibitors as specifically targeted antiviral therapy for" exact="hepatitis" post="CFuture Virol.4200927729310.2217/fvl.09.720161209 54Romero-LÃ³pezC.Berzal-HerranzA.The role of the RNA-RNA interactome in"/>
 <result pre="CFuture Virol.4200927729310.2217/fvl.09.720161209 54Romero-LÃ³pezC.Berzal-HerranzA.The role of the RNA-RNA interactome in the" exact="hepatitis C" post="virus life cycleInt. J. Mol. Sci.21202010.3390/ijms21041479 55NguyenC.B.KotturiH.WarisG.MohammedA.ChandrakesanP.MayR.SurebanS.WeygantN.QuD.RaoC.V.DhanasekaranD.N.BronzeM.S.HouchenC.W.AliN.(Z)-3,5,4â€™-trimethoxystilbene limits hepatitis"/>
 <result pre="hepatitis C virus life cycleInt. J. Mol. Sci.21202010.3390/ijms21041479 55NguyenC.B.KotturiH.WarisG.MohammedA.ChandrakesanP.MayR.SurebanS.WeygantN.QuD.RaoC.V.DhanasekaranD.N.BronzeM.S.HouchenC.W.AliN.(Z)-3,5,4â€™-trimethoxystilbene limits" exact="hepatitis C" post="and cancer pathophysiology by blocking microtubule dynamics and cell-cycle"/>
 <result pre="life cycleInt. J. Mol. Sci.21202010.3390/ijms21041479 55NguyenC.B.KotturiH.WarisG.MohammedA.ChandrakesanP.MayR.SurebanS.WeygantN.QuD.RaoC.V.DhanasekaranD.N.BronzeM.S.HouchenC.W.AliN.(Z)-3,5,4â€™-trimethoxystilbene limits hepatitis C and" exact="cancer" post="pathophysiology by blocking microtubule dynamics and cell-cycle progressionCanc. Res.7620164887489610.1158/0008-5472.CAN-15-2722"/>
 <result pre="MacreW.Neil TowersG.H.An ethnopharmacological examination of Virola elongata bark: a South" exact="American" post="arrow poisonJ.Â Ethnopharmacol.121984759210.1016/0378-8741(84)90087-46097773 57LeeS.YoonK.D.LeeM.ChoY.ChoiG.JangH.KimB.JungD.H.OhJ.G.KimG.W.OhJ.W.JeongY.J.KwonH.J.BaeS.K.MinD.H.WindischM.P.HeoT.H.LeeC.Identification of a resveratrol tetramer as"/>
 <result pre="57LeeS.YoonK.D.LeeM.ChoY.ChoiG.JangH.KimB.JungD.H.OhJ.G.KimG.W.OhJ.W.JeongY.J.KwonH.J.BaeS.K.MinD.H.WindischM.P.HeoT.H.LeeC.Identification of a resveratrol tetramer as a potent inhibitor of" exact="hepatitis C" post="virus helicaseBr. J. Pharmacol.173201619121110.1111/bph.1335826445091 58LeeS.MailarK.Il KimM.ParkM.KimJ.MinD.H.HeoT.H.BaeS.K.ChoiW.LeeC.Plant-derived purification, chemical synthesis,"/>
 <result pre="resveratrol dimer, viniferin, as an HCV Replication inhibitorViruses11201911810.3390/v11100890 59JangH.RyooS.R.KimY.K.YoonS.KimH.HanS.W.ChoiB.S.KimD.E.MinD.H.Discovery of" exact="hepatitis C" post="virus NS3 helicase inhibitors by a multiplexed, high-throughput helicase"/>
 <result pre="Resting Peripheral Brood Mononuclear Cells, Monocyte-Derived Macrophages, and Selected Drug-Resistant" exact="Isolated" post="with Nucleosid Analoguese Combined with a Natural Product2000Resveratrol 72ChanC.N.TrinitÃ©B.LevyD.N.Potent"/>
 <result pre="Cells, Monocyte-Derived Macrophages, and Selected Drug-Resistant Isolated with Nucleosid Analoguese" exact="Combined" post="with a Natural Product2000Resveratrol 72ChanC.N.TrinitÃ©B.LevyD.N.Potent inhibition of HIV-1 replication"/>
 <result pre="Nat. Prod.61199835135310.1021/np970519h9544565 76CardinA.D.SmithP.L.HydeL.BlankenshipD.T.BowlinT.L.SchroederK.StaudermanK.A.TaylorD.L.TymsA.S.Stilbene disulfonic acids: CD4 antagonists that block human" exact="immunodeficiency" post="virus type-1 growth at multiple stages of the virus"/>
 <result pre="screening of synthetic and natural products for AIDS-antiviral activityJ.Â Natl." exact="Cancer" post="Inst.81198957758610.1093/jnci/81.8.5772495366 80BedoyaL.M.del OlmoE.SanchoR.BarbozaB.BeltrÃ¡nM.GarcÃ­a-CadenasA.E.SÃ¡nchez-PalominoS.LÃ³pez-PÃ©rezJ.L.MuÃ±ozE.FelicianoA.S.AlcamÃ­J.Anti-HIV activity of stilbene-related heterocyclic compoundsBioorg. Med."/>
 <result pre="of early host antiviral responsesFront. Cell. Infect. Microbiol.9201912710.3389/fcimb.2019.0012731114761 97HorowitzR.AierstuckS.WilliamsE.A.MelbyB.Herpes simplex" exact="virus infection" post="in a university health population: clinical manifestations, epidemiology, and"/>
 <result pre="early host antiviral responsesFront. Cell. Infect. Microbiol.9201912710.3389/fcimb.2019.0012731114761 97HorowitzR.AierstuckS.WilliamsE.A.MelbyB.Herpes simplex virus" exact="infection" post="in a university health population: clinical manifestations, epidemiology, and"/>
 <result pre="clinical manifestations, epidemiology, and implicationsJ.Â Am. Coll. Health592010697410.1080/07448481.2010.48371120864431 98BarnabasR.V.WasserheitJ.N.HuangY.JanesH.MorrowR.FuchsJ.MarkK.E.CasapiaM.MehrotraD.V.BuchbinderS.P.CoreyL.Impact of" exact="herpes" post="simplex virus type 2 on HIV-1 acquisition and progression"/>
 <result pre="and implicationsJ.Â Am. Coll. Health592010697410.1080/07448481.2010.48371120864431 98BarnabasR.V.WasserheitJ.N.HuangY.JanesH.MorrowR.FuchsJ.MarkK.E.CasapiaM.MehrotraD.V.BuchbinderS.P.CoreyL.Impact of herpes simplex virus" exact="type 2" post="on HIV-1 acquisition and progression in an HIV vaccine"/>
 <result pre="trial (the step study)J.Â Acquir. Immune Defic. Syndr.57201123824410.1097/QAI.0b013e31821acb521860356 99BradyR.C.BernsteinD.I.Treatment of" exact="herpes" post="simplex virus infectionsAntivir. Res.612004738110.1016/j.antiviral.2003.09.00614670580 100FrobertE.CortayJ.C.OokaT.NajioullahF.ThouvenotD.LinaB.MorfinF.Genotypic detection of acyclovir-resistant HSV-1:"/>
 <result pre="human and animal virusesAdv. Virol.20151842411184241710.1155/2015/1842412015 102ChenX.WangZ.YangZ.WangJ.XuY.xiang TanR.LiE.Houttuynia cordata blocks HSV" exact="infection" post="through inhibition of NF-ÎºB activationAntivir. Res.92201134134510.1016/j.antiviral.2011.09.00521951655 103ChenX.QiaoH.LiuT.YangZ.XuL.XuY.GeH.M.TanR.X.LiE.Inhibition of herpes"/>
 <result pre="HSV infection through inhibition of NF-ÎºB activationAntivir. Res.92201134134510.1016/j.antiviral.2011.09.00521951655 103ChenX.QiaoH.LiuT.YangZ.XuL.XuY.GeH.M.TanR.X.LiE.Inhibition of" exact="herpes" post="simplex virus infection by oligomeric stilbenoids through ROS generationAntivir."/>
 <result pre="through inhibition of NF-ÎºB activationAntivir. Res.92201134134510.1016/j.antiviral.2011.09.00521951655 103ChenX.QiaoH.LiuT.YangZ.XuL.XuY.GeH.M.TanR.X.LiE.Inhibition of herpes simplex" exact="virus infection" post="by oligomeric stilbenoids through ROS generationAntivir. Res.952012303610.1016/j.antiviral.2012.05.00122584350 104De ClercqE.Antiviral"/>
 <result pre="inhibition of NF-ÎºB activationAntivir. Res.92201134134510.1016/j.antiviral.2011.09.00521951655 103ChenX.QiaoH.LiuT.YangZ.XuL.XuY.GeH.M.TanR.X.LiE.Inhibition of herpes simplex virus" exact="infection" post="by oligomeric stilbenoids through ROS generationAntivir. Res.952012303610.1016/j.antiviral.2012.05.00122584350 104De ClercqE.Antiviral"/>
 <result pre="Thai medicinal plant: mechanism of action and therapeutic efficacy on" exact="cutaneous" post="HSV-1 infection in miceAntivir. Res.802008627010.1016/j.antiviral.2008.05.00218565600 106ShenJ.ZhouQ.LiP.WangZ.LiuS.HeC.ZhangC.XiaoP.Update on phytochemistry and"/>
 <result pre="plant: mechanism of action and therapeutic efficacy on cutaneous HSV-1" exact="infection" post="in miceAntivir. Res.802008627010.1016/j.antiviral.2008.05.00218565600 106ShenJ.ZhouQ.LiP.WangZ.LiuS.HeC.ZhangC.XiaoP.Update on phytochemistry and pharmacology of"/>
</results>
